Skip to main content
. 2022 May 9;10(5):741. doi: 10.3390/vaccines10050741

Figure 4.

Figure 4

(A) Comparison of difference in total anti-SARS-CoV-2 antibody levels between first (after 8 months) and second determination (after 10 months) in the groups of women and men with and without a history of COVID-19. The data are presented as median (minimum–maximum). (B) Comparison of difference in total anti-SARS-CoV-2 antibody levels between first (after 8 months) and second determination (after 10 months) in the groups of patients under and over the age of 50 with and without a history of COVID-19. The data are presented as median (minimum–maximum). (C) Comparison of difference in total anti-SARS-CoV-2 antibody levels between first (after 8 months) and second determination (after 10 months) in the group of patients with normal and increased BMI with and without a history of COVID-19. The data are presented as median (minimum–maximum). (D) Comparison of difference in total anti-SARS-CoV-2 antibody levels between first (after 8 months) and second determination (after 10 months) in the groups of patients with and without coexisting diseases with and without a history of COVID-19. The data are presented as median (minimum–maximum). (E) Comparison of difference in total anti-SARS-CoV-2 antibody levels between first (after 8 months) and second determination (after 10 months) in the groups of medical and non-medical workers with and without a history of COVID-19. The data are presented as median (minimum–maximum).